Challenges for Australia's bio/nanopharma policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Industrial renewal in the bio/nanopharma sector is important for the long term strength of the Australian economy and for the health of its citizens. A variety of factors, however, may have caused inadequate attention to focus on systematically promoting domestic generic and small biotechnology manufacturers in Australian health policy. Despite recent clarifications of 'springboarding' capacity in intellectual property legislation, federal government requirements for specific generic price...[Show more]
|Collections||ANU Research Publications|
|Source:||Australia and New Zealand Health Policy|
|Faunce_Challenges.pdf||380.75 kB||Adobe PDF|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.